Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to Its Board of Directors
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced the final closing of a $ …